Health Advisory: CDC updated antiviral guidance

Actions Requested


As Omicron cases surge in our region and healthcare system capacity is strained, we welcome news of additional tools to combat the pandemic and reduce the burden on our healthcare systems. We are working with community partners to establish equitable and accessible distribution of these therapeutics as they become available.

In the original clinical trial, sotrovimab treatment reduced the risk of the composite endpoints of hospitalization and death in high risk patients by 85%. Based on pre-print in vitro data, CDC currently believes sotrovimab is the only monoclonal antibody under EUA that retains efficacy against Omicron variant. Because sotrovimab supplies are limited—we expect to receive 550 doses for the entire state for the next month—it is imperative that we prioritize it for the highest risk individuals. See the risk tiers in CDC’s distribution plan for details.

We hope to have availability of oral antivirals very soon via local partner pharmacies for people in the middle tier high risk group. We plan to have detailed information to help providers access these medications as soon as they become available locally.

Additional information

COVID-19 vaccine

COVID-19 testing

COVID-19 therapeutics

Department of Health and Human Services (HHS) allocates monoclonal antibody and oral antiviral supplies to each state. DOH distributes doses to enrolled providers. Providers must enroll in Healthcare Partner Ordering Portal (HPoP) to manage COVID-19 therapeutics. Email to register for HPoP training, held Tuesdays at 9 a.m.

COVID-19 prevention patient education

Share the following materials with patients.

Immediately report COVID-19

Fax the positive lab results or a completed Reportable Disease Fax Form to our confidential fax (360) 813-1168. If needed, call Kitsap Public Health by calling (360) 728-2235.

Additional Resources